BioSpace News Archive

FDA

Pfizer’s Tafamidis Approved in First for Rare Heart Disease

The approval is a first for the the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The drug has a list price of $225,000.

May 6, 2019
·
3 min read
·
Alex Keown
Business

Artificial Intelligence is Ramping up in Drug Development

AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.

May 6, 2019
·
5 min read
·
Mark Terry
Adrenomed AG takes part in three upcoming conferences

Adrenomed AG, the vascular integrity company, announced its participation at three upcoming conferences in Europe and the USA.

May 6, 2019
·
1 min read
Publications of Secarna Pharmaceuticals’ immuno-oncology data in peer-reviewed scientific journals support potential of LNAplusTM antisense oligonucleotide platform for discovering novel cancer therapies

New strategies urgently needed to prevent tumors from evading the immune system and to make them more susceptible to attack by immune cells

May 6, 2019
·
6 min read
Bio NC

Your Feedback Matters! The Right Opportunity

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your ‘right opportunity’ to consider a new job.

May 6, 2019
·
1 min read
·
Editorial Staff
Pharm Country

Biotech Support Group to exhibit at the 67th ASMS Conference on Mass Spectrometry & Allied Topics

Biotech Support Group will exhibit at the annual ASMS Conference, June 2-6, 2019 in Atlanta, GA.

May 6, 2019
·
3 min read
Drug Development

Cytokinetics’ ALS Treatment Fails to Hit Endpoints in Phase II, Company Notes Several Positive Results

Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.

May 6, 2019
·
3 min read
·
Alex Keown
Drug Development

Neurocrine’s Opicapone Plus Levodopa Improves Parkinson’s Symptoms

San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.

May 6, 2019
·
3 min read
·
Mark Terry
Policy

Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review

Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver

May 6, 2019
·
8 min read
Deals

Banco Sabadell Gives ADL Bionatur Solutions An Upside Potential Of 78%

Sales estimated to double in 2019 and exceed EUR 50 million

May 6, 2019
·
2 min read